The CD112R/CD112 axis: a breakthrough in cancer immunotherapy
The recent discovery of immune checkpoint inhibitors is a significant milestone in cancer immunotherapy research. However, some patients with primary or adaptive drug resistance might not benefit from the over...
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Taofei Zeng, Yuqing Cao, Tianqiang Jin, Yu Tian, Chaoliu Dai and Feng Xu Tags: Review Source Type: research